All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
During ICML 2019 in Lugano, Switzerland, the Lymphoma Hub were pleased to speak to Paolo Ghia from University Vita-Salute San Raffaele, Milan, IT, about how the results of the phase III ASCEND trial might change treatment practice of relapsed/refractory chronic lymphocytic leukemia (CLL).
Paolo Ghia discusses how the multicenter, international study compared a classic chemotherapy treatment with a chemotherapy-free treatment, and with a novel BTK inhibitor. He mentions how, for the first time, two chemotherapy-free treatments were compared.
How will the results of the phase III ASCEND trial change treatment practice of R/R CLL?
Management of patients with CLL after venetoclax discontinuation
Results from a study addressing the optimal treatment regimen after discontinuation of venetoclax and the impact of venetoclax resistance on the efficacy of subsequent therapies.
SOHO 2019 | Standard of care in mantle cell lymphoma
Lymphoma Hub coverage from SOHO 2019 on standard of care regimens in mantle cell lymphoma
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox